Association of adverse events with antibiotic use in hospitalized patients

JAMA Internal Medicine

Volumn 177, Issue 9, 2017, Pages 1308-1315

  Tamma, Pranita D ^a   Avdic, Edina ^b   Li, David X ^c   Dzintars, Kathryn ^b   Cosgrove, Sara E ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFAZOLIN; CEFEPIME; CEFPODOXIME; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; LINEZOLID; MEROPENEM; METRONIDAZOLE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; DRUG FEVER; DRUG USE; FEMALE; GENERAL PRACTICE; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOSITIS; NAUSEA; NEUROLOGIC DISEASE; PANCREATITIS; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SKIN DISEASE; SYSTEMIC THERAPY; UNIVERSITY HOSPITAL; URTICARIA; VOMITING; CLASSIFICATION; CLINICAL PRACTICE; DRUG ADMINISTRATION ROUTE; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH CARE FACILITY; HEALTH SERVICE; HOSPITALIZATION; MIDDLE AGED; NEEDS ASSESSMENT; PREVENTION AND CONTROL; STANDARDS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION ROUTES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INPATIENTS; MALE; MEDICAL OVERUSE; MIDDLE AGED; NEEDS ASSESSMENT; PATIENTS' ROOMS; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 85029121230     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.1938     Document Type: Article

References (29)

1. Magill SS, Edwards JR, Beldavs ZG, et al; Emerging Infections Program Healthcare- Associated Infections and Antimicrobial Use Prevalence Survey Team. Prevalence of antimicrobial use in US acute care hospitals, May-September 2011. JAMA. 2014; 312(14): 1438-1446.
2. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: Current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med. 2003; 163(8): 972-978.
3. Camins BC, KingMD,Wells JB, et al. Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: A randomized controlled trial. Infect Control Hosp Epidemiol. 2009; 30(10): 931-938.
4. IngramPR, Seet JM, Budgeon CA, Murray R. Point-prevalence study of inappropriate antibiotic use at a tertiary Australian hospital. Intern Med J. 2012; 42(6): 719-721.
5. Cosgrove SE, Seo SK, Bolon MK, et al; CDC Prevention Epicenter Program. Evaluation of postprescription review and feedback as amethod of promoting rational antimicrobial use: A multicenter intervention. Infect Control Hosp Epidemiol. 2012; 33(4): 374-380.
6. Tamma PD, Avdic E, Keenan JF, et al. What is the more effective antibiotic stewardship intervention: Pre-prescription authorization or post-prescription review with feedback? Clin Infect Dis. 2017; 64(5): 537-543.
7. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014; 14: 13.
8. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012; 67(3): 742-748.
9. Liu NW, Shatagopam K, Monn MF, et al. Risk for Clostridium difficile infection after radical cystectomy for bladder cancer: Analysis of a contemporary series. Urol Oncol. 2015; 33(12): 503.e17-503.e22.
10. Kuster SP, RudnickW, Shigayeva A, et al; Toronto Invasive Bacterial Diseases Network. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: Results from prospective surveillance. Clin Infect Dis. 2014; 59(7): 944-952.
11. Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL. Risk of hepatotoxicity associated with fluoroquinolones: A national case-control safety study. Am J Health Syst Pharm. 2014; 71(1): 37-43.
12. TorresMJ, Blanca M, Fernandez J, et al; ENDA; EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy. 2003; 58(10): 961-972.
13. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008; 47(6): 735-743.
14. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with communityacquired pneumonia. Antimicrob Agents Chemother. 1997; 41(9): 1965-1972.
15. Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2017; 64(5): 666-674.
16. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 cohort studies. Br J Clin Pharmacol. 1998; 46(5): 505-511.
17. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. Am FamPhysician. 2013; 87(5): 331-336.
18. Lin RY, Nuruzzaman F, Shah SN. Incidence and impact of adverse effects to antibiotics in hospitalized adults with pneumonia. J HospMed. 2009; 4(2): E7-E15.
19. Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol. 2015; 135(3): 745-52.e5.
20. Werner NL, Hecker MT, Sethi AK, Donskey CJ. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis. 2011; 11: 187.
21. Blumenthal KG, Kuhlen JL Jr,Weil AA, et al. Adverse drug reactions associated with ceftaroline use: A 2-center retrospective cohort. J Allergy Clin Immunol Pract. 2016; 4(4): 740-746.
22. Epic Care Everywhere Network. https://www.epic.com/CareEverywhere/. Accessed December 6, 2016.
23. Johns Hopkins Medicine Antibiotic Guidelines 2015-2016. http://www.hopkinsmedicine.org/amp. Accessed February 5, 2017.
24. Goldstein SL, Kirkendall E, Nguyen H, et al. Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatrics. 2013; 132(3): E756-e767.
25. Centers for Disease Control and Prevention. Antimicrobial resistant phenotype definitions. https://www.cdc.gov/nhsn/pdfs/ps-analysis -resources/phenotype-definitions.pdf. Accessed January 26, 2017.
26. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol. 1994; 89(4): 519-523.
27. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults: A prospective case-controlled epidemiologic study. Arch Intern Med. 1986; 146(1): 95-100.
28. Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf. 2007; 30(8): 705-713.
29. Meropol SB, Localio AR,Metlay JP. Risks and benefits associated with antibiotic use for acute respiratory infections: A cohort study. Ann FamMed. 2013; 11(2): 165-172.